173 related articles for article (PubMed ID: 34070369)
1. Folate Receptor Beta as a Direct and Indirect Target for Antibody-Based Cancer Immunotherapy.
Roy AG; Robinson JM; Sharma P; Rodriguez-Garcia A; Poussin MA; Nickerson-Nutter C; Powell DJ
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070369
[TBL] [Abstract][Full Text] [Related]
2. Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells.
Lynn RC; Poussin M; Kalota A; Feng Y; Low PS; Dimitrov DS; Powell DJ
Blood; 2015 May; 125(22):3466-76. PubMed ID: 25887778
[TBL] [Abstract][Full Text] [Related]
3. A folate receptor beta-specific human monoclonal antibody recognizes activated macrophage of rheumatoid patients and mediates antibody-dependent cell-mediated cytotoxicity.
Feng Y; Shen J; Streaker ED; Lockwood M; Zhu Z; Low PS; Dimitrov DS
Arthritis Res Ther; 2011 Apr; 13(2):R59. PubMed ID: 21477314
[TBL] [Abstract][Full Text] [Related]
4. Production of a High-affinity Monoclonal Antibody Reactive with Folate Receptors Alpha and Beta.
Nagai T; Furusho Y; Li H; Hasui K; Matsukita S; Sueyoshi K; Yanagi M; Hatae M; Takao S; Matsuyama T
Monoclon Antib Immunodiagn Immunother; 2015 Jun; 34(3):181-90. PubMed ID: 26090596
[TBL] [Abstract][Full Text] [Related]
5. High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity.
Lynn RC; Feng Y; Schutsky K; Poussin M; Kalota A; Dimitrov DS; Powell DJ
Leukemia; 2016 Jun; 30(6):1355-64. PubMed ID: 26898190
[TBL] [Abstract][Full Text] [Related]
6. Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia.
Zhao X; Singh S; Pardoux C; Zhao J; Hsi ED; Abo A; Korver W
Haematologica; 2010 Jan; 95(1):71-8. PubMed ID: 19648166
[TBL] [Abstract][Full Text] [Related]
7. CD16
Williams BA; Wang XH; Leyton JV; Maghera S; Deif B; Reilly RM; Minden MD; Keating A
Haematologica; 2018 Oct; 103(10):1720-1729. PubMed ID: 29976748
[TBL] [Abstract][Full Text] [Related]
8. Selective recruitment of γδ T cells by a bispecific antibody for the treatment of acute myeloid leukemia.
Ganesan R; Chennupati V; Ramachandran B; Hansen MR; Singh S; Grewal IS
Leukemia; 2021 Aug; 35(8):2274-2284. PubMed ID: 33526858
[TBL] [Abstract][Full Text] [Related]
9. Examination of CD302 as a potential therapeutic target for acute myeloid leukemia.
Lo TH; Abadir E; Gasiorowski RE; Kabani K; Ramesh M; Orellana D; Fromm PD; Kupresanin F; Newman E; Cunningham I; Hart DNJ; Silveira PA; Clark GJ
PLoS One; 2019; 14(5):e0216368. PubMed ID: 31075107
[TBL] [Abstract][Full Text] [Related]
10. T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia.
Hoseini SS; Vadlamudi M; Espinosa-Cotton M; Tran H; Feng Y; Guo HF; Xu H; Cheung I; Cheung NV
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035113
[TBL] [Abstract][Full Text] [Related]
11. CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia.
Jiang YP; Liu BY; Zheng Q; Panuganti S; Chen R; Zhu J; Mishra M; Huang J; Dao-Pick T; Roy S; Zhao X; Lin J; Banik G; Hsi ED; Mandalam R; Junutula JR
Blood Adv; 2018 Jul; 2(14):1738-1749. PubMed ID: 30037800
[TBL] [Abstract][Full Text] [Related]
12. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
Mani R; Rajgolikar G; Nunes J; Zapolnik K; Wasmuth R; Mo X; Byrd JC; Lee DA; Muthusamy N; Vasu S
Cytotherapy; 2020 Jul; 22(7):369-376. PubMed ID: 32303428
[TBL] [Abstract][Full Text] [Related]
13. Folate Receptor Beta Designates Immunosuppressive Tumor-Associated Myeloid Cells That Can Be Reprogrammed with Folate-Targeted Drugs.
Cresswell GM; Wang B; Kischuk EM; Broman MM; Alfar RA; Vickman RE; Dimitrov DS; Kularatne SA; Sundaram CP; Singhal S; Eruslanov EB; Crist SA; Elzey BD; Ratliff TL; Low PS
Cancer Res; 2021 Feb; 81(3):671-684. PubMed ID: 33203700
[TBL] [Abstract][Full Text] [Related]
14. Novel fully human anti-CD47 antibodies stimulate phagocytosis and promote elimination of AML cells.
Wang C; Sun C; Li M; Xia B; Wang Y; Zhang L; Zhang Y; Wang J; Sun F; Lu S; Zhu J; Huang J; Zhang Y
J Cell Physiol; 2021 Jun; 236(6):4470-4481. PubMed ID: 33206395
[TBL] [Abstract][Full Text] [Related]
15. A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells.
Arvindam US; van Hauten PMM; Schirm D; Schaap N; Hobo W; Blazar BR; Vallera DA; Dolstra H; Felices M; Miller JS
Leukemia; 2021 Jun; 35(6):1586-1596. PubMed ID: 33097838
[TBL] [Abstract][Full Text] [Related]
16. Targeting folate receptor β positive tumor-associated macrophages in lung cancer with a folate-modified liposomal complex.
Tie Y; Zheng H; He Z; Yang J; Shao B; Liu L; Luo M; Yuan X; Liu Y; Zhang X; Li H; Wu M; Wei X
Signal Transduct Target Ther; 2020 Jan; 5(1):6. PubMed ID: 32296026
[TBL] [Abstract][Full Text] [Related]
17. Characterization of SGN-CD123A, A Potent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia.
Li F; Sutherland MK; Yu C; Walter RB; Westendorf L; Valliere-Douglass J; Pan L; Cronkite A; Sussman D; Klussman K; Ulrich M; Anderson ME; Stone IJ; Zeng W; Jonas M; Lewis TS; Goswami M; Wang SA; Senter PD; Law CL; Feldman EJ; Benjamin DR
Mol Cancer Ther; 2018 Feb; 17(2):554-564. PubMed ID: 29142066
[TBL] [Abstract][Full Text] [Related]
18. Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.
Ågerstam H; Karlsson C; Hansen N; Sandén C; Askmyr M; von Palffy S; Högberg C; Rissler M; Wunderlich M; Juliusson G; Richter J; Sjöström K; Bhatia R; Mulloy JC; Järås M; Fioretos T
Proc Natl Acad Sci U S A; 2015 Aug; 112(34):10786-91. PubMed ID: 26261316
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of an immunotoxin to folate receptor beta in the intra-articular treatment of antigen-induced arthritis.
Nagai T; Kyo A; Hasui K; Takao S; Matsuyama T
Arthritis Res Ther; 2012 May; 14(3):R106. PubMed ID: 22551402
[TBL] [Abstract][Full Text] [Related]
20. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC.
Busfield SJ; Biondo M; Wong M; Ramshaw HS; Lee EM; Ghosh S; Braley H; Panousis C; Roberts AW; He SZ; Thomas D; Fabri L; Vairo G; Lock RB; Lopez AF; Nash AD
Leukemia; 2014 Nov; 28(11):2213-21. PubMed ID: 24705479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
